Market Overview

Savient Pharma Elects Genzyme's David Meeker to Board

Related SVNT
Savient to Sell Substantially All Assets To Crealta Pharmaceuticals for $120.4M
Savient Pharmaceuticals Announces Agreement on Use of Cash Collateral

Savient Pharma (NASDAQ: SVNT) announced today that David Meeker, M.D., President and Chief Executive Officer of Genzyme, a Sanofi Company, has been elected to Savient's Board of Directors, effective January 7, 2013.  In addition, Savient announced the resignation from the Company's Board of William F. Owen, Jr., M.D., who is relocating to Qatar to serve as Chief Executive Officer of the Sidra Medical and Research Center, a groundbreaking medical, research and education institution that focuses on the health and wellbeing of women and children in Doha, Qatar.  With the election of Dr. Meeker and the departure of Dr. Owen, the number of Savient Board members remains seven.

Posted-In: News Management


Most Popular

Related Articles (SVNT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free